Comparative Pharmacology
Head-to-head clinical analysis: BAYER EXTRA STRENGTH ASPIRIN FOR MIGRAINE PAIN versus CHILDREN S IBUPROFEN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: BAYER EXTRA STRENGTH ASPIRIN FOR MIGRAINE PAIN versus CHILDREN S IBUPROFEN.
BAYER EXTRA STRENGTH ASPIRIN FOR MIGRAINE PAIN vs CHILDREN'S IBUPROFEN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Irreversibly inhibits cyclooxygenase-1 (COX-1) and cyclooxygenase-2 (COX-2) enzymes, reducing prostaglandin and thromboxane synthesis, which leads to analgesic, antipyretic, and anti-inflammatory effects.
Non-selective cyclooxygenase (COX-1 and COX-2) inhibitor, reducing prostaglandin synthesis, which mediates inflammation, pain, and fever.
500-1000 mg orally every 4-6 hours as needed; maximum 4000 mg in 24 hours.
Oral: 200-400 mg every 6-8 hours as needed; maximum daily dose: 1200 mg (OTC) or 3200 mg (prescription).
None Documented
None Documented
Aspirin half-life is 15-20 minutes due to rapid hydrolysis to salicylate. Salicylate terminal half-life is 2-3 hours at low doses, up to 15-30 hours at high doses or with toxicity. At analgesic doses (600-1000 mg), effective half-life is ~3-4 hours, requiring q4-6h dosing.
2-4 hours (terminal elimination half-life in children; may be prolonged in neonates or hepatic impairment)
Renal excretion of salicylate and its metabolites (salicyluric acid, salicyl phenolic glucuronide, salicyl acyl glucuronide, gentisic acid). Approximately 90% of a dose is excreted renally; 10% via bile/feces. Excretion is dose- and pH-dependent: alkaline urine increases clearance.
Renal: 90% (primarily as conjugated metabolites, <10% unchanged); biliary/fecal: minor
Category D/X
Category D/X
NSAID / Antiplatelet
NSAID